BACKGROUND: In early breast cancer patients, the effects of hormonal therapy (tamoxifen and aromatase inhibitors) on plasma fibroblast growth factor 21 (FGF-21), lipid levels and body composition have not yet been investigated. Therefore, we aimed to analyze the relationship between FGF-21 and body composition as well as the effects of tamoxifen and aromatase inhibitors on plasma lipid levels, FGF-21, and body composition.
METHODS: A total of 72 patients were treated with either tamoxifen or aromatase inhibitors due to their menopausal status after adjuvant radiotherapy. Each patient was followed-up over a period of 1 year. Changes in body composition and serum lipid profile, glucose and FGF-21 levels were evaluated. We recorded the type of hormonal therapy, body mass index, waist-to-hip ratio, lipid profile, and FGF-21 levels both at the beginning and after 12 months.
RESULTS: There was a statistically significant decrease in serum FGF-21 levels after 12 months of adjuvant endocrine therapy (46 ± 19.21 pg/ml vs. 30.99 ± 13.81 pg/ml, p< 0.001). Total body water (p< 0.001), serum glucose (p= 0.036) and triglyceride levels (p< 0.001) also exhibited a significant decrease. The decreases in total cholesterol and low-density lipoprotein were not statistically significant. Likewise, high-density lipoprotein increased after adjuvant endocrine therapy, although it did not reach statistical significance. The changes in body composition, glucose, lipid profile and FGF-21 were similar in tamoxifen and aromatase inhibitor groups. A positive correlation was found between basal weight, fat mass, fat-free mass and serum FGF-21 levels; however, the correlation was maintained only for the fat-free mass at the 12th month.
CONCLUSION: As part of the present study, we suggest that both tamoxifen and aromatase inhibitors can reduce FGF-21 levels independently of body compositions, and these drugs can provide antihyperlipidemic, antidiabetic and cardio-protective effects. We also recommend that serum FGF-21 level can be utilized as a tumor biomarker in early-stage breast cancer and for monitoring purposes. FGF-21 levels may help physicians estimate prognosis, too. Further studies with larger populations may shed light on the role of FGF-21 in breast cancer.
SiegelR, MaJ, ZouZ and JemalA. Cancer statistics. CA Cancer J Clin64 (2014), 19-29.
2.
YueW and SantenRJ. Aromatase inhibitors: Rationale for use following antiestrogen therapy. SeminOncol23(9) (1999), 21-27.
3.
BruggemeierRW. Overview of the pharmacology of the aromatase inactivator exemestane. Breast Cancer Res Treat74 (2002), 177-185.
4.
LeviF, RandimbisonL, TeVC and La VecchiaC. Long-term mortality of women with a diagnosis of breast cancer. Oncology63 (2002), 266-269.
5.
HarveyJM, ClarkGM, OsborneCK and AllredDC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol17 (1999), 1474-1481.
6.
OsborneCK, ElledgeRM and FuquaSAW. Estrogen receptors in breast cancer therapy. SciMed3 (1996), 32-41.
7.
DutertreM and SmithCL. Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther295 (2000), 431-437.
8.
FisherB, DignamJ, BryantJ et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the national surgical adjuvant breast and bowel project B-14 randomized trial. J Natl Cancer Inst93 (2001), 684-690.
9.
CamposSM. Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist9 (2004), 126-136.
10.
McKeehanWL, WangF and KanM. The heparin sulfate-fibroblast growth factor family: Diversity of structure and function. Prog Nucleic Acid Res Mol Biol59 (1998), 135-176.
11.
OrnitzDM and ItohN. Fibroblast growth factors. Genome Biol2 (2001), REVIEWS3005.
12.
ItohN and OrnitzDM. Evolution of the FGF and FGFR gene families. Trends Genet20 (2004), 563-569.
13.
KharitonenkovA, ShiyanovaTL, KoesterA et al. FGF-21 as a novel metabolic regulator. J Clin Invest115 (2005), 1627-1635.
14.
LiH, ZhangJ and JiaW, Fibroblast growth factor 21 a novel metabolic regulator from pharmacology to physiology. Front Med7 (2013), 25-30.
15.
FisherFM, KleinerS, DourisN et al. FGF-21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. Genes Dev26 (2012), 271-281.
16.
EtoK, TumenbayarB, NagashimaS et al. Distinct association of serum FGF-21 or adiponectin levels with clinical parameters in patients with type 2 diabetes. Diabetes Res Clin Pract89 (2010), 52-57.
17.
MaiK, SchwarzF, BobbertT et al. Relation between fibroblast growth factor-21, adiposity, metabolism, and weight reduction. Metabolism60 (2011), 306-311.
18.
Cuevas-RamosD, Almeda-ValdesP, Aguilar-SalinasCA et al. The role of fibroblast growth factor 21 (FGF-21) on energy balance, glucose and lipid metabolism. Curr Diabetes Rev5 (2009), 216-220.
19.
OgawaY, KurosuH, YamamotoM et al. Klotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci USA104 (2007), 7432-7437.
20.
WenteW, EfanovAM, BrennerM et al. Fibroblast growth factor-21 improves pancreatic - cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes55 (2006). 2470-2478.
21.
XuJ, LloydDJ, HaleC et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes58 (2009), 250-259.
22.
GaichG, ChienJY, FuH et al. The effects of LY2405319, an FGF-21 analog, in obese human subjects with type 2 diabetes. Cell Metab18 (2013), 333-340.
23.
CheungBM and DengHB. Fibroblast growth factor 21: A promising therapeutic target in obesity-related disease. Expert Rev Cardiovasc Ther12 (2014). 659-666.
24.
CoskunT, BinaHA, SchneiderMA et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology149 (2008). 6018-6027.
25.
GorarS, CulhaC, UcZA et al. Serum fibroblast growth factor 21 levels in polycystic ovary syndrome. Gynecol Endocrinol26 (2010), 819-826.
26.
LiH, ZhangJ and JiaW. Fibroblast growth factor 21: A novel metabolic regulator from pharmacology to physiology. Front Med7 (2013), 25-30.
27.
LiH, FangQ, GaoF et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol53 (2010), 934-940.
28.
FisherFM, ChuiPC, AntonellisPJ et al. Obesity is a fibroblast growth factor 21 (FGF-21)-resistant state. Diabetes59 (2010), 2781-2789.
29.
Diaz-DelfinJ, HondaresE, IglesiasR et al. TNF-alpha represses beta-Klotho expression and impairs FGF-21 action in adipose cells; involvement of JNK1 in the FGF-21 pathway. Endocrinology153 (2012), 4238-4245.
30.
MrazM, BartlovaM, LacinovaZ et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol71 (2009), 369-375.
31.
Lenart-LipińskaM, Matyjaszek-MatuszekB, GernandW et al. Serum fibroblast growth factor 21 is predictive of combined cardiovascular morbidity and mortality in patients with type 2 diabetes at a relatively short-term follow-up. Diabetes Res Clin Pract101 (2013), 194-200.
32.
AnSY, LeeMS, YiSA et al. Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques. Diabetes Res Clin Pract96 (2012), 196-203.
33.
ShenY, MaX, ZhouJ et al. Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc Diabetol12 (2013), 124.
34.
TyynismaaH, RaivioT, HakkarainenA et al. Liver fat but not other adiposity measures influence circulating FGF-21 levels in healthy young adult wins. J Clin Endocrinol Metab96 (2011), 351-355.
35.
DushayJ, ChuiPC, GopalakrishnanGS et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology139 (2010), 456-463.
36.
ChenC, CheungBM, TsoAW et al. High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: A 5.4-year population-based prospective study in Chinese subjects. Diabetes Care34 (2011), 2113-2115.
37.
MashiliFL, AustinRL, DeshmukhAS et al. Direct effects of FGF-21 on glucose uptake in human skeletal muscle: Implications for type 2 diabetes and obesity. Diabetes Metab Res Rev27 (2011), 286-297.
38.
ReinehrT, WoelfleJ, WunschR et al, Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: A longitudinal analysis. The Journal of Clinical Endocrinology and Metabolism97 (2012), 2143-2150.
39.
StraczkowskiM, Karczewska-KupczewskaM, AdamskaA et al. Serum fibroblast growth factor 21 in human obesity: Regulation by insulin infusion and relationship with glucose and lipid oxidation. International Journal of Obesity37 (2013), 1386-1390.
40.
LynaeJH, KristaC, AmbikaPA et al. Fibroblast growth factor-21, body composition, and insulin resistance in pre-pubertal and early pubertal males and females. Clinical Endocrinology82 (2015), 550-556.
41.
SerapBS, TeslimeA, MedineCC et al. Fibroblast growth factor 21 and its relation to metabolic parameters in women with polycystic ovary syndrome. Scandinavian Journal of Clinical and Laboratory Investigation74 (2014), 465-469.
42.
HernandezRK, SorensenHT, JacobsenJ et al. Tamoxifen treatment in Danish breast cancer patients and 5-year risk of arterial atherosclerotic events: A null association. Cancer Epidemiol Biomarkers Prev17 (2008), 2509-2511.
43.
PitrodaSP, KhodarevNN, BeckettMA, KufeDW and WeichselbaumRR. Muc1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc Natl Acad Sci USA106 (2009), 5837-5841.
44.
EstevaFJ and HortobagyiGN. Comparative assessment of lipid effects of endocrine therapy for breast cancer: Implications for cardiovascular disease prevention in postmenopausal women. Breast15 (2006), 301-312.
45.
RossouwJE, AndersonGL, PrenticeRL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA288 (2002), 321-333.
46.
NicolaidesC, ElisafM, BairaktariE et al. The effect of the aromatase inhibitor letrozole on lipid parameters in postmenopausal women with breast cancer. A Preliminary Report. Ann. Oncol11(4) (2000), 12.
47.
ElisafMS, BairaktariET, NicolaidesC et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur. J. Cancer37 (2001), 1510-1513.
48.
Harper-WynneC, RossG, SacksN and DowsettM. Effects of the aromatase inhibitor letrozole on breast cell proliferation and bone/lipid indices in healthy postmenopausal women: Pilot prevention study. Breast Cancer Res Treat69 (2001), 225.
49.
DewarJ, NabholtzJ-MA, BonneterreJ et al. The effect of anastrozole (ArimidexTM) on serum lipids - data from a randomized comparison of anastrozole (AN) vs Tamoxifen (TAM) in postmenopausal (PM) women with advanced breast cancer (ABC). Breast Cancer Res Treat64 (2000), 51.
50.
WojtackiJ, Lesniewski-KmakK, PawlakW et al. Anastrozole therapy and lipid profile: An update. Eur J Cancer2 (2004), 142.
51.
WojtackiJ and Lesniewski-KmakK. Biochemical markers of the risk for cardiovascular disease in women with early breast cancer treated with anastrozole. Eur J Cancer3 (2005), 105.
52.
KnottME, RanuncoloSM, NuñezM, ArmanascoE, PuricelliL and De LorenzoMS. Levels of Fibroblast Growth Factor 21 (FGF-21) in serum as diagnostic biomarker in patients with breast cancer. Cancer Res75 (2015), 1577.
